List view / Grid view

James Graham (Recce Pharmaceuticals)

 

article

Recce Pharmaceuticals’ synthetic approach to combatting AMR

As antimicrobial resistance continues to advance, novel therapeutics are needed…

5 June 2024 | By

As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…

article

Antimicrobial resistance with Recce Pharmaceuticals

In this exclusive interview, Drug Target Review's Taylor Mixides interviews…

16 November 2023 | By

In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of…